Fractyl Health company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

fractyl.com

Executives

7

Board of Directors

4

Fractyl Health Board of Directors

4 Board of directors

Fractyl Health has 4 board of directors, including Brian Dovey.

Name

Firm

Work History

Other Seats

Brian Dovey

Brian Dovey has been a partner of Domain Associates since 1988, where he has led investments, and he has served on the board of directors of more than 35 private and public companies. Prior to Domain, Mr. Dovey spent six years at Rorer Group (now part of Sanofi-Aventis). As president of Rorer from 1986 to 1988, he was the primary architect of this company’s strategic shift to pharmaceuticals, which resulted in a doubling of annual sales to approximately $1 billion. Prior to that, Mr. Dovey was president of Survival Technology, a start-up medical products company whose sales growth placed it in the top 10 of the Inc. 100. He received his BA in Mathematics from Colgate University and his MBA from Harvard Business School. Mr. Dovey was former chairman and currently serves on the board of directors of both the Center for Venture Education (Kauffman Fellows Program) and the Wistar Institute, a leader in preclinical biomedical research in the nonprofit sector. He previously served as chairman of the National Venture Capital Association and was a trustee of the University of Pennsylvania School of Nursing and Sanford-Burnham Medical Research Institute.

Fractyl Health

Chris Gabrieli

Chris Gabrieli, a partner in Bessemer's Cambridge, Mass. office, joined the firm in 1986 to launch its healthcare practice. In 25 years of investing with Bessemer, he has invested broadly in healthcare and other industries. He currently focuses on biotechnology, healthcare services and education. Chris is closely involved in Bessemer’s investments in cancer-therapeutics firm AVEO Pharmaceuticals and biopharmaceutical firms Acceleron Pharma, Proteon, Oxagen and Transave. He serves on the board of digital textbook pioneer Flat World Knowledge. Among his past portfolio companies are biopharmaceutical company Affymax ( NASDAQ: AFFY); electronic health-record solutions company Allscripts (NASDAQ:MDRX); Isis Pharmaceuticals, a company that is the leading innovator in RNA-targeting pharmaceuticals; PerSeptive BioSystems, a maker of instruments for protein synthesis (acquired by Perkin-Elmer); Sirtris Pharmaceuticals, a developer of small-molecule drugs (NASDAQ: SIRT, acquired by GlaxoSmithKline); TravCorps, a pioneering healthcare-staffing company acquired by Cross Country Healthcare (CCRN); and VistaCare (NASDAQ:VSTA), a provider of hospice-care services. Prior to his career at Bessemer, Chris founded and served as CEO of GMIS, a healthcare-software company he co-founded and helped build, take public and sell to the leading industry consolidator, McKesson (NYSE: MCK). Bessemer was an investor in GMIS. Chris graduated from Harvard University with a B.A. in history and science and completed two years of the Columbia College of Physicians & Surgeons M.D. program. He is also a leader in education innovation and is founder and chairman of the National Center on Time & Learning and a lecturer at the Harvard Graduate School of Education.

Fractyl Health

Hemant Taneja

Hemant Taneja is an investor, founder, and author. He is the managing partner of the venture capital firm General Catalyst, which partners with mission-driven founders from seed to growth stage and beyond to build companies that are fundamentally aligned with the long-term interests of society. Hemant is an early investor in market-leading companies like Digit, Grammarly, Gusto, Livongo (acquired by Teladoc), Mindstrong, Samsara, Snap (NYSE: SNAP), and Stripe. His primary investment thesis, known as “economies of unscale,” explores how 21st-century founders leverage AI-based mass personalization techniques to innovate and build platforms across all sectors of the economy. In his 2018 book “Unscaled,” Hemant built upon that thesis to articulate the need for accountability, transparency, and explainability in AI technologies as they permeate deeper into daily life. Hemant’s upcoming book, “Intended Consequences” (McGraw Hill, 2022), lays out an actionable framework for founders, entrepreneurs, leadership teams, and investors on how to build and maintain a “responsible innovation” company— a company built for growth and for societal good that withstands the test of time. The book explains why a company’s mindset—its intent to do good, avoid harmful consequences, and innovate responsibly—is not enough. That mindset must be supported by a business model, a mechanism that leaders must intentionally and proactively build along with the company from the ground up, one that incentivizes and rewards the organization for fulfilling its intentions. Hemant is also the founder and executive chairman of Commure, a company that has partnered with major health systems to modernize the software infrastructure for the healthcare space since its inception in 2017. His recently published book, “UnHealthcare,” co-authored with Dr. Stephen Klasko, CEO of Jefferson Health, lays out their thesis on how the healthcare system needs to transform into a health assurance system to bring consumerism, affordability, and rational economic behavior to this important sector. In addition to his investment work, Hemant is the Co-Founder of Advanced Energy Economy, an organization focused on transforming energy policy in America; and is a Founding Board Member of the Khan Lab School, a nonprofit K-12 school dedicated to classroom innovation. He sits on the Board of Fellows for the Stanford School of Medicine and teaches a course at the college on AI, Entrepreneurship, and Society. Hemant has 5 degrees from MIT.

Fractyl Health

John Simon

At Sigma Prime, John invests in both new and existing technology businesses. Special interests include mobile and SAAS software companies and disruptive technology companies. John has been a recipient of the Massachusetts Technology Leadership Council "Investor of the Year" Award. John's current Sigma investments and/or Board Memberships include: Phenom People, BlueConic, CloudBees, nToggle (acq'd Magnite), and Kwicr (acq'd, InStart Logic). Previous to joining Sigma, John was a Co-founder and Managing Director of General Catalyst Partners, where he was on the Board of Directors or otherwise involved with: Jumptap (acq'd, Millennial Media/AOL), Paydiant (acq'd, PayPal), OwnCloud, Big Fish Games (acq'd, Churchill Downs), SignalDemand (acq'd, PROS), BetterLesson, Mocospace, Thumb, Swirl, Swoop, CyPhy Works, BionX, Aidin, Tear Science (acq'd Johnson & Johnson), Fractyl, Corvia Medical, OvaScience (NASDAQ: OVAS), Taleo (NASDAQ:TLEO, acq'd, Oracle for $2B), m-Qube (acq'd, VeriSign), ProfitLogic (acq'd, Oracle), Maven Networks (acq'd, Yahoo!), Bullhorn Software (acq'd, Vista Equity), Quickplay Media (acq'd, Madison Dearborn), BzzAgent (acq'd, Dunn Humby/Tesco), and Outstart (acq'd, Kenexa/IBM). Previously, John was the Founder, Chairman and CEO of UroMed Corporation, which had its IPO in 1994 and was subsequently merged to form Alliant Medical Technologies. Prior to that, he led marketing and sales at Adaptive Networks and was a vc at Highland Capital Partners and Charles River Ventures. In addition to Sigma Prime, John invests via Ventureforgood, an investment holding company set up by John to make winning investments and dedicate the "carried interest" (a portion of the ultimate realized gains) to enable better outcomes for children and families via life-changing non-profits like The GreenLight Fund. Early stage Vfg portfolio company investments include sector-leading companies like Evergage (acq'd ,Salesforce), Decibel Insight (acq'd, Medallia), Frequency Therapeutics, Grammarly, BlueConic, Densify, Crayon, Clear Ballot Group, BlockFi, Flipside Crypto, HelloTeam, Super Equip.health, Bicycle Health, Garner Health & Conformal Medical; these companies now have an aggregate market value approaching $7 billion. John is a member of the World Presidents’ Organization (WPO). He’s a co-founder and current trustee of the Steppingstone Foundation (www.tsf.org). In addition, he’s continued his involvement with the non-profit sector by founding the GreenLight Fund (www.greenlightfund.org), which spurs the replication and growth of innovative non-profits.

Fractyl Health

Name

Brian Dovey

Chris Gabrieli

Hemant Taneja

John Simon

Firm

Work History

Brian Dovey has been a partner of Domain Associates since 1988, where he has led investments, and he has served on the board of directors of more than 35 private and public companies. Prior to Domain, Mr. Dovey spent six years at Rorer Group (now part of Sanofi-Aventis). As president of Rorer from 1986 to 1988, he was the primary architect of this company’s strategic shift to pharmaceuticals, which resulted in a doubling of annual sales to approximately $1 billion. Prior to that, Mr. Dovey was president of Survival Technology, a start-up medical products company whose sales growth placed it in the top 10 of the Inc. 100. He received his BA in Mathematics from Colgate University and his MBA from Harvard Business School. Mr. Dovey was former chairman and currently serves on the board of directors of both the Center for Venture Education (Kauffman Fellows Program) and the Wistar Institute, a leader in preclinical biomedical research in the nonprofit sector. He previously served as chairman of the National Venture Capital Association and was a trustee of the University of Pennsylvania School of Nursing and Sanford-Burnham Medical Research Institute.

Chris Gabrieli, a partner in Bessemer's Cambridge, Mass. office, joined the firm in 1986 to launch its healthcare practice. In 25 years of investing with Bessemer, he has invested broadly in healthcare and other industries. He currently focuses on biotechnology, healthcare services and education. Chris is closely involved in Bessemer’s investments in cancer-therapeutics firm AVEO Pharmaceuticals and biopharmaceutical firms Acceleron Pharma, Proteon, Oxagen and Transave. He serves on the board of digital textbook pioneer Flat World Knowledge. Among his past portfolio companies are biopharmaceutical company Affymax ( NASDAQ: AFFY); electronic health-record solutions company Allscripts (NASDAQ:MDRX); Isis Pharmaceuticals, a company that is the leading innovator in RNA-targeting pharmaceuticals; PerSeptive BioSystems, a maker of instruments for protein synthesis (acquired by Perkin-Elmer); Sirtris Pharmaceuticals, a developer of small-molecule drugs (NASDAQ: SIRT, acquired by GlaxoSmithKline); TravCorps, a pioneering healthcare-staffing company acquired by Cross Country Healthcare (CCRN); and VistaCare (NASDAQ:VSTA), a provider of hospice-care services. Prior to his career at Bessemer, Chris founded and served as CEO of GMIS, a healthcare-software company he co-founded and helped build, take public and sell to the leading industry consolidator, McKesson (NYSE: MCK). Bessemer was an investor in GMIS. Chris graduated from Harvard University with a B.A. in history and science and completed two years of the Columbia College of Physicians & Surgeons M.D. program. He is also a leader in education innovation and is founder and chairman of the National Center on Time & Learning and a lecturer at the Harvard Graduate School of Education.

Hemant Taneja is an investor, founder, and author. He is the managing partner of the venture capital firm General Catalyst, which partners with mission-driven founders from seed to growth stage and beyond to build companies that are fundamentally aligned with the long-term interests of society. Hemant is an early investor in market-leading companies like Digit, Grammarly, Gusto, Livongo (acquired by Teladoc), Mindstrong, Samsara, Snap (NYSE: SNAP), and Stripe. His primary investment thesis, known as “economies of unscale,” explores how 21st-century founders leverage AI-based mass personalization techniques to innovate and build platforms across all sectors of the economy. In his 2018 book “Unscaled,” Hemant built upon that thesis to articulate the need for accountability, transparency, and explainability in AI technologies as they permeate deeper into daily life. Hemant’s upcoming book, “Intended Consequences” (McGraw Hill, 2022), lays out an actionable framework for founders, entrepreneurs, leadership teams, and investors on how to build and maintain a “responsible innovation” company— a company built for growth and for societal good that withstands the test of time. The book explains why a company’s mindset—its intent to do good, avoid harmful consequences, and innovate responsibly—is not enough. That mindset must be supported by a business model, a mechanism that leaders must intentionally and proactively build along with the company from the ground up, one that incentivizes and rewards the organization for fulfilling its intentions. Hemant is also the founder and executive chairman of Commure, a company that has partnered with major health systems to modernize the software infrastructure for the healthcare space since its inception in 2017. His recently published book, “UnHealthcare,” co-authored with Dr. Stephen Klasko, CEO of Jefferson Health, lays out their thesis on how the healthcare system needs to transform into a health assurance system to bring consumerism, affordability, and rational economic behavior to this important sector. In addition to his investment work, Hemant is the Co-Founder of Advanced Energy Economy, an organization focused on transforming energy policy in America; and is a Founding Board Member of the Khan Lab School, a nonprofit K-12 school dedicated to classroom innovation. He sits on the Board of Fellows for the Stanford School of Medicine and teaches a course at the college on AI, Entrepreneurship, and Society. Hemant has 5 degrees from MIT.

At Sigma Prime, John invests in both new and existing technology businesses. Special interests include mobile and SAAS software companies and disruptive technology companies. John has been a recipient of the Massachusetts Technology Leadership Council "Investor of the Year" Award. John's current Sigma investments and/or Board Memberships include: Phenom People, BlueConic, CloudBees, nToggle (acq'd Magnite), and Kwicr (acq'd, InStart Logic). Previous to joining Sigma, John was a Co-founder and Managing Director of General Catalyst Partners, where he was on the Board of Directors or otherwise involved with: Jumptap (acq'd, Millennial Media/AOL), Paydiant (acq'd, PayPal), OwnCloud, Big Fish Games (acq'd, Churchill Downs), SignalDemand (acq'd, PROS), BetterLesson, Mocospace, Thumb, Swirl, Swoop, CyPhy Works, BionX, Aidin, Tear Science (acq'd Johnson & Johnson), Fractyl, Corvia Medical, OvaScience (NASDAQ: OVAS), Taleo (NASDAQ:TLEO, acq'd, Oracle for $2B), m-Qube (acq'd, VeriSign), ProfitLogic (acq'd, Oracle), Maven Networks (acq'd, Yahoo!), Bullhorn Software (acq'd, Vista Equity), Quickplay Media (acq'd, Madison Dearborn), BzzAgent (acq'd, Dunn Humby/Tesco), and Outstart (acq'd, Kenexa/IBM). Previously, John was the Founder, Chairman and CEO of UroMed Corporation, which had its IPO in 1994 and was subsequently merged to form Alliant Medical Technologies. Prior to that, he led marketing and sales at Adaptive Networks and was a vc at Highland Capital Partners and Charles River Ventures. In addition to Sigma Prime, John invests via Ventureforgood, an investment holding company set up by John to make winning investments and dedicate the "carried interest" (a portion of the ultimate realized gains) to enable better outcomes for children and families via life-changing non-profits like The GreenLight Fund. Early stage Vfg portfolio company investments include sector-leading companies like Evergage (acq'd ,Salesforce), Decibel Insight (acq'd, Medallia), Frequency Therapeutics, Grammarly, BlueConic, Densify, Crayon, Clear Ballot Group, BlockFi, Flipside Crypto, HelloTeam, Super Equip.health, Bicycle Health, Garner Health & Conformal Medical; these companies now have an aggregate market value approaching $7 billion. John is a member of the World Presidents’ Organization (WPO). He’s a co-founder and current trustee of the Steppingstone Foundation (www.tsf.org). In addition, he’s continued his involvement with the non-profit sector by founding the GreenLight Fund (www.greenlightfund.org), which spurs the replication and growth of innovative non-profits.

Other Seats

Fractyl Health

Fractyl Health

Fractyl Health

Fractyl Health

Fractyl Health Management Team

7 Team Members

Fractyl Health has 7 executives. Fractyl Health's current Founder, President is Jay Caplan.

Name

Work History

Title

Status

Jay Caplan

Founder, President

Current

Harith Rajagopalan

Founder, Chief Executive Officer

Current

Lisa Davidson

Chief Financial Officer

Current

Juan Carlos Lopez Talavera

Chief Medical Officer

Current

Diane Marcou

Chief Financial Officer

Former

Name

Jay Caplan

Harith Rajagopalan

Lisa Davidson

Juan Carlos Lopez Talavera

Diane Marcou

Work History

Title

Founder, President

Founder, Chief Executive Officer

Chief Financial Officer

Chief Medical Officer

Chief Financial Officer

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.